APUS (Apimeds Pharmaceuticals Us) 3-Month Share Buyback Ratio: 0.00% (As of Mar. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APUS Apimeds Pharmaceuticals Us Inc APUS
14 GF Score
Price $0.65
! 3 Warning Signs
View Full Analysis

What is Apimeds Pharmaceuticals Us 3-Month Share Buyback Ratio?

Apimeds Pharmaceuticals Us APUS +0.93% 14 3-Month Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Apimeds Pharmaceuticals Us's current 3-Month Share Buyback Ratio was 0.00%.

Apimeds Pharmaceuticals Us  (AMEX:APUS) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Apimeds Pharmaceuticals Us 3-Month Share Buyback Ratio Related Terms

APUS vs KAYS, BIOE, BFRI: 3-Month Share Buyback Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Apimeds Pharmaceuticals Us's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apimeds Pharmaceuticals Us 3-Month Share Buyback Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apimeds Pharmaceuticals Us's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Apimeds Pharmaceuticals Us's 3-Month Share Buyback Ratio falls into.


APUS
14GF Score
Apimeds Pharmaceuticals Us Inc APUS
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apimeds Pharmaceuticals Us 3-Month Share Buyback Ratio Calculation

Apimeds Pharmaceuticals Us's 3-Month Share Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2025 ) - Shares Outstanding (EOP) (Mar. 2026 )) / Shares Outstanding (EOP) (Dec. 2025 )
=(12.576 - 12.576) / 12.576
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of 0.00 mean?
Apimeds Pharmaceuticals Us (APUS) has a 3-Month Share Buyback Ratio of 0.00 as of Mar. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Apimeds Pharmaceuticals Us and its competitors.
Is Apimeds Pharmaceuticals Us' 3-Month Share Buyback Ratio too high?
Apimeds Pharmaceuticals Us' current 3-Month Share Buyback Ratio is 0.00. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' 3-Month Share Buyback Ratio compare to KAYS and BIOE?
Apimeds Pharmaceuticals Us' 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Month Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Apimeds Pharmaceuticals Us and its competitors. Apimeds Pharmaceuticals Us's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current 3-Month Share Buyback Ratio of 0.00. The current 3-Month Share Buyback Ratio is 0.00. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current 3-Month Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apimeds Pharmaceuticals Us Business Description

Address 100 Matawan Road, Suite 325, Matawan, NJ, USA, 07747
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score

Get the complete analysis for APUS

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price